Associated Papers
Proteome-Wide Analysis of Functional Phosphosites in the FGFR Family of Proteins: Insights from Large-Scale Phosphoproteomic Analysis.
Palollathil A et al.
Proteomes, 2026
Recurrent resistance mutations to lirafugratinib inform treatment sequencing in FGFR2-driven tumors.
Facchinetti F et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
The heterozygous c.2241G>C variation in FGFR2 may cause autosomal dominant Kirner's deformity in a Chinese Han pedigree.
Ma M et al.
Bmc Medical Genomics, 2026
DyVarMap: Integrating Conformational Dynamics and Interpretable Machine Learning for Cancer-Associated Missense Variant Classification in FGFR2.
Lian Y et al.
Bioengineering (basel, Switzerland), 2026
Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations.
Tangermann C et al.
Nature Genetics, 2026
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
Rational Design and Identification of ISM7594 as a Tissue-Agnostic FGFR2/3 Inhibitor.
Wang Y et al.
Journal of Medicinal Chemistry, 2025
Prevalence and biological impact of clinically relevant gene fusions in head and neck cancers.
Hoskins EL et al.
Npj Precision Oncology, 2025
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling.
Goyal L et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2025
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.
Facchinetti F et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2024
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.
Rodón J et al.
Nature Medicine, 2024
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors.
Garmezy B et al.
Cancer Research Communications, 2024
Elucidating the Role of Wildtype and Variant FGFR2 Structural Dynamics in (Dys)Function and Disorder.
Lian Y et al.
International Journal of Molecular Sciences, 2024
Postpartum related intrahepatic cholangiocarcinoma with FGFR2 fusion and severe hyperbilirubinemia with response to FGFR inhibitor pemigatinib: case report and review.
Washburn L et al.
Journal of Gastrointestinal Oncology, 2023
Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants.
Lin Q et al.
Communications Chemistry, 2022
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Zingg D et al.
Nature, 2022
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions.
Repetto M et al.
Expert Review of Clinical Pharmacology, 2021
Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance.
Krook MA et al.
British Journal of Cancer, 2021
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib.
Silverman IM et al.
Cancer Discovery, 2021
Oncogenic fusion protein FGFR2-PPHLN1: Requirements for biological activation, and efficacy of inhibitors.
Li F et al.
Translational Oncology, 2020
Identification of pathogenic missense mutations using protein stability predictors.
Gerasimavicius L et al.
Scientific Reports, 2020
Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations.
Lima NC et al.
International Journal of Molecular Sciences, 2020
Molecular basis for receptor tyrosine kinase A-loop tyrosine transphosphorylation.
Chen L et al.
Nature Chemical Biology, 2020
The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
Roskoski R
Pharmacological Research, 2020
A Conserved Allosteric Pathway in Tyrosine Kinase Regulation.
Marsiglia WM et al.
Structure (london, England : 1993), 2019
Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy.
Krook MA et al.
Cold Spring Harbor Molecular Case Studies, 2019
The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
Zill OA et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2018
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.
Goyal L et al.
Cancer Discovery, 2017
Elucidation of a four-site allosteric network in fibroblast growth factor receptor tyrosine kinases.
Chen H et al.
Elife, 2017
Ectrodactyly and Lethal Pulmonary Acinar Dysplasia Associated with Homozygous FGFR2 Mutations Identified by Exome Sequencing.
Barnett CP et al.
Human Mutation, 2016
FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
International Journal of Molecular Medicine, 2016
Activating mutations cluster in the "molecular brake" regions of protein kinases and do not associate with conserved or catalytic residues.
Molina-Vila MA et al.
Human Mutation, 2014
A novel FGFR2 mutation in tyrosine kinase II domain, L617F, in Crouzon syndrome.
Suh YJ et al.
Journal of Cellular Biochemistry, 2014
Structure-functional prediction and analysis of cancer mutation effects in protein kinases.
Dixit A et al.
Computational and Mathematical Methods in Medicine, 2014
Predicting the impact of deleterious mutations in the protein kinase domain of FGFR2 in the context of function, structure, and pathogenesis--a bioinformatics approach.
C GP et al.
Applied Biochemistry and Biotechnology, 2013